2015
Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients
Vicknasingam B, Dazali MN, Singh D, Schottenfeld RS, Chawarski MC. Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients. Drug And Alcohol Dependence 2015, 152: 164-169. PMID: 25935736, DOI: 10.1016/j.drugalcdep.2015.04.007.Peer-Reviewed Original ResearchConceptsBUP/NXNX treatmentGeneral practitionersPast monthOpiate positive urine testsOptimal treatment effectivenessRoutine toxicology testingToxicology testingBuprenorphine/naloxonePositive urine testUrine toxicology testingIllicit opiate useInjection of heroinInjection of drugsCross-sectional surveyMaintenance treatmentPatient surveyUrine testingUrine testsTreatment responseOpiate usePatient experiencePatientsDispensing practicesDrug use
2012
Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
Ruger JP, Chawarski M, Mazlan M, Ng N, Schottenfeld R. Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia. PLOS ONE 2012, 7: e50673. PMID: 23226534, PMCID: PMC3514172, DOI: 10.1371/journal.pone.0050673.Peer-Reviewed Original ResearchConceptsHeroin dependenceCost-effectiveness ratioSecondary outcomesOutcome measuresDrug usePlacebo-controlled clinical trialFirst heroin useIncremental cost-effectiveness ratioSocietal costsInjection drug useSecondary outcome measuresPrimary outcome measureIllicit opiate useIncremental treatment costNaltrexone treatmentPrimary outcomeMedication costsPlacebo interventionClinical trialsHeroin abstinenceOpiate useHeroin useBuprenorphineTreatment retentionNaltrexone
2010
Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial
Chawarski MC, Zhou W, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial. Drug And Alcohol Dependence 2010, 115: 237-239. PMID: 21159452, PMCID: PMC3076517, DOI: 10.1016/j.drugalcdep.2010.09.024.Peer-Reviewed Original ResearchConceptsHIV risk reduction counselingMethadone maintenance treatmentRisk reduction counselingIllicit opiate useHIV risk behaviorsBehavioral drugReduction counselingClinical trialsOpiate useMMT servicesRisk behaviorsPrimary outcome measurePilot clinical trialTime of enrollmentSignificant baseline differencesHeroin-dependent individualsNegative test resultsMMT clinicsDaily medicationMaintenance treatmentMMT programBaseline differencesOutcome measuresMMT groupTreatment retention
2007
Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence
Chawarski MC, Fiellin DA, O'Connor PG, Bernard M, Schottenfeld RS. Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. Journal Of Substance Use And Addiction Treatment 2007, 33: 411-415. PMID: 17512157, PMCID: PMC3632440, DOI: 10.1016/j.jsat.2007.03.004.Peer-Reviewed Original ResearchConceptsOutpatient clinical settingPatch testingDrug useClinical settingSweat testingEfficacy of buprenorphinePrimary care settingRandomized clinical trialsSelf-reported drug usePositive urine resultsSweat test resultsDrug use monitoringUrine toxicologyOpioid dependenceOutpatient treatmentUrine testingClinical trialsCare settingsOpiate useOpiate dependenceUrine resultsStudy participantsLevel of agreementToxicology testsLow acceptability
1999
Plasma concentrations of buprenorphine 24 to 72 hours after dosing
Chawarski MC, Schottenfeld RS, O’Connor P, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug And Alcohol Dependence 1999, 55: 157-163. PMID: 10402160, DOI: 10.1016/s0376-8716(98)00192-6.Peer-Reviewed Original ResearchConceptsDose scheduleWithdrawal symptomsPlasma concentrationsDaily buprenorphine doseHigh-dose scheduleThrice-weekly scheduleAdministration of buprenorphineOpiate-dependent subjectsHigher plasma concentrationsUse of heroinBuprenorphine doseDaily administrationOutpatient clinicPlasma levelsSublingual administrationAgonist effectsOpiate useHeroin useLow doseHigh doseBuprenorphine solutionMg/70High dosesConcentration 24Dependent subjects